

JOHN E. EDWARDS, JR., MD

CURRICULUM VITAE

PERSONAL HISTORY:

Business address: Research and Education Institute
at Harbor-UCLA Medical Center
Saint Johns Cardiovascular Research Center
Division of Infectious Diseases
1124 W. Carson St.
Torrance, CA 90502

Work Phone: _____

Fax: _____

E-mail: _____

Home address: _____

Home phone: _____

Date of Birth: _____

Place of Birth: _____

Citizenship: _____

EDUCATION AND TRAINING:

Pomona College, Claremont, CA Degree: Bachelor in Arts in Zoology	1960-1964
University of California, Irvine College of Medicine Degree: Doctor of Medicine	1964-1968
Harbor-UCLA Medical Center, Torrance, CA Internship in Straight Medicine	1968-1969
Harbor-UCLA Medical Center, Torrance, CA Residency in Internal Medicine	1969-1971
Harbor-UCLA Medical Center, Torrance, CA Fellowship in Infectious Diseases	1971-1973

LICENSURE:

State of California, _____
Drug Enforcement Agency, _____

CERTIFICATION:

Diplomate, American Board of Internal Medicine

Internal Medicine	1972
Subspecialty of Infectious Diseases	1974
Internal Medicine (Recertification)	1980

PROFESSIONAL EXPERIENCE:

Professor of Medicine (In Residence)	July 1986-
UCLA School of Medicine, Los Angeles, CA	
Chief, Division of Infectious Diseases	July 1981-
Harbor-UCLA Medical Center, Torrance, CA	
Attending Physician, Department of Medicine	July 1975-
Harbor-UCLA Medical Center, Torrance, CA	
Guest Worker	Oct. 1984 – July 1985
National Institutes of Health, Laboratory of Clinical Investigation and Laboratory of Immunology	
Bethesda, MD	
Associate Chief, Division of Infectious Diseases	Jan. 1981 – June 1981
Harbor-UCLA Medical Center, Torrance, CA	
Associate Professor of Medicine (In Residence)	July 1980 – July 1986
UCLA School of Medicine, Los Angeles, CA	
Assistant Professor of Medicine (In Residence)	July 1975 – July 1980
UCLA School of Medicine, Los Angeles, CA	
Staff Physician, Division of Infectious Diseases	July 1975 – Jan. 1981
Harbor-UCLA Medical Center, Torrance, CA	
Internist, Infectious Disease Consultant and Epidemiologist	July 1973 – June 1975
U.S. Naval Regional Medical Center, Camp Pendleton, CA	

PROFESSIONAL ACTIVITIES:

COMMITTEES:

Harbor-UCLA Medical Center
(Current)

Department of Medicine, Search Committee for Chair, Dept. of Medicine
1999 - 2001
Harbor-UCLA REI, Collegium Board of Directors, 1998 –
Department of Medicine, Executive Committee
Department of Medicine, Tabbarah-Kennamer Fellowship Fund

(Previous)

Harbor-UCLA REI, Research Committee, Chairman, 2000 – 2001
Harbor-UCLA REI, Subcommittee on Administrative Policies,
Chair, 2000 – 2001
Harbor-UCLA REI, Finance Committee, Vice Chair, 2000- 2001
Harbor-UCLA REI, Research Space Committee, 1999 - 2001
Harbor-UCLA REI, Board of Directors, 1999 – 2001
Harbor-UCLA REI, Executive Committee, 1999 – 2001
Harbor-UCLA REI, Task Force for Development, Vice Chair,
1999 – 2001
Department of Medicine, Search Committee for Chair, HIV Service
1999 - 2001
Harbor-UCLA REI, Chairman of Nomination Committee for REI
Board of Directors, 1999
Harbor-UCLA REI, Research Committee, Vice-President, 1997-99
Harbor-UCLA REI, Administrative Policy Committee Chairman, 1990-
1996
Harbor-UCLA REI, Search Committee for Chief, Molecular Medicine
Division, 1999
Department of Medicine, Search Committee for Chief of Cardiology
Internship Interview Committee, 1998-1999
Harbor-UCLA REI-Fund Development Committee, 1993-1996,
Past Chairman
Harbor-UCLA REI, Search Committee for President and CEO of REI,
1996
Harbor-UCLA REI, Research Committee, Secretary
Harbor-UCLA REI, Research Administration Task Force Fund Raising
Committee, Co-Chairman
Department of Medicine Reunion Committee
Dean's Advisory Committee for AIDS Research, Executive Committee
Reunion Committee, Department of Medicine, Chairman
Education Committee, General Internal Medicine, American Board of
Internal Medicine
Geriatrics Advisory Committee
Harbor-UCLA AIDS Task Force
Chairman, Harbor-UCLA AIDS Symposium (week-long symposium with
local and national speakers)
Harbor-UCLA Sabbatical Committee, Chairman Search Committee,
Wadsworth VA, Chief of Infectious Diseases
Grossman Society, UCLA School of Medicine
Internship Selection Committee
Residency Selection Committee
Research Administration Committee

Infectious Disease Search Committee, UCLA
Chairman, Medical Intern Residents Education Committee
UCLA Faculty Retreat Committee, 1983
Student Education Committee
John Leonard Memorial Committee, Chairman
Hospital Infection Control Committee
Search Committee, Harbor-UCLA, Chief of Dept. of Emergency Medicine

NATIONAL COMMITTEES AND ACTIVITIES

Member, American Board of Internal Medicine, Infectious Disease
Subspecialty, 2000-present
NIH- Clinical Center Scientific Board of Directors 2003-Present
FDA- Anti-Infective Advisory Committee- nominated for membership-
appointment pending 2003
Infectious Diseases Society of American Public Policy Committee,
Chairman, 2001-present.
NIH-Summit on Development of ID Therapeutics, Subproject Co-leader,
1999.
NIH-Site Review of NCI Pediatric Oncology Section, 1999.
NIH-Search Committee for Director of Microbiology of NIAID, 1999
NIH-Chairman of NCI-DTP/AIDS Advisory Panel, 1998-1999
NIH-NIAID Council, Ad hoc Guest, 1996,
Wellcome Foundation Advisory Board for Molecular Medical Mycology
Course, 1996- 2001.
NIH-Chairman, Advisory Panel for Chronic Lyme Disease Program,
1996- 2002
Wellcome Foundation Advisory Board for Fungal Research Program,
1995-2001
Center for Disease Control-Mycology Program Review Panel, 1995
NIH-Office of AIDS Research Review Panel for Opportunistic Infections,
1995
NIH Focus Group Member for Anthony Fauci, 1995
NIH Ad hoc Reviewer, BM-2 Study Section
National Institutes of Health-NIAID Mycoses Study Group Chairman,
Candida Sub-Project, 1993 – 2001. Executive Committee Member
2001-present
Infectious Diseases Society of America – Program Committee, 1991, 1992
Joseph Susman Memorial Award Committee, Infectious Disease Society
Of America, Chairman, 1988, 1989

MEMBERSHIPS

American Board of Internal Medicine, Subspecialty Board of Infect. Dis.
American Society for Microbiology
Association of American Physicians

Infectious Diseases Society of America, Counselor, 1997-2000
International Immunocompromised Host Society, Councilor, 2002-present
Western Society for Clinical Investigation
Western Association of Physicians, Counselor, 2000-present

**EDITORIAL
CONSULTANT**

Journal of Infectious Diseases
Western Journal of Medicine
American Journal of Medicine
Archives of Internal Medicine
Annals of Internal Medicine
New England Journal of Medicine
Arthritis and Rheumatism
Infection and Immunity
Journal of Veterinary and Human Mycology
Journal of Pediatric Research
Journal of Clinical Investigation
Journal of Immunology
Mayo Clinical Proceedings

**EDITORIAL
BOARD**

Infectious Disease Alert, 1981 - 1987
Diagnostic Microbiology and Infectious Diseases, 1981 – 1983

**EDITORIAL
STAFF**

Associate Editor, Clinical Infectious Diseases, 1989 – 1998
Editorial Board, Journal of Infectious Diseases, 1994 – present

**INVITED
PROFESSIONAL
CONSULTATIONS**

National Institutes of Health. Review of Bone Marrow Transplant Grant.
Site Visit. Sloan Kettering, New York. February 1972
National Institutes of Health. Symposium on Amphotericin B
Methyl Ester. Presentation: Feasibility of Use of Amphotericin B
Methyl Ester in Disseminated Candidiasis. February 1977.
National Institutes of Health. Review of Yale University Oncology Grant.
Site Visit. Yale University, New Haven, CT. June 1980.
University of California, Davis. Ad hoc Committee Member.
Amphotericin B Methyl Ester. March 1981.
Veterans Administration Merit Review Board. Ad hoc Reviewer.
1985, 1986
United States – Israel Bi-national Science Foundation. Grant Reviewer.
1987.
Lilly Corporation: Design of Clinical Trials for Anti-fungals.
October 1987.
Hybritech Corporation: Candida Monoclonal Antibody Studies. 1987
Smith, Klein, and French Corporation. Mycology Study Group. 1988.

National Institutes of Health – Mycology Workshop Program Planning Committee
National Institutes of Health Study Section, Bacteriology and Mycology.
Ad hoc Reviewer, February 1988, 1990, 1993.
National Institutes of Health – NIAID Council Ad hoc Member, February 1994.
Cetus Corporation. Consultant on the Use of Biological Response Modifiers. 1990.
Pfizer Pharmaceuticals Antifungal Advisory Board – 1991-present
Biofor Corporation, 1991 – 1995
Scientific Advisory Board – Myco Pharmaceuticals, 1991 – 1996.
Grant Reviewer, New Zealand Health Research Council. 1994, 1996.
Pliva Scientific Advisory Board, 2001 -present
Merck Scientific Advisory Board on antifungals, 2001-present

OTHER TEACHING:

International Courses: Co-founder and Resident Instructor, Woods Hole Course on Molecular Mycology of Pathogenic Fungi, 1997 – present.
Co-founder ASM International Meeting on the Biology and Pathogenesis of Candida, 1987. Meets every two years.

HONORS AND SPECIAL AWARDS:

Academic Honor Society, University of California, Irvine, College of Medicine	1967
J. Gordon Hattfield Award for Excellence in Surgery, University of California, Irvine, College of Medicine	1968
Merck Awards for Academic Excellence, University of California, Irvine, College of Medicine	1968
Outstanding Straight Medicine Intern Award, Harbor-UCLA Medical Center	1969
Academic Investigator Award, National Institutes of Health	1975 – 1978
Distinguished Faculty Teaching Award, Department of Medicine, Harbor-UCLA Medical Center	1978
Alpha Omega Alpha, Alumnus Member, University of California, Irvine, College of Medicine	1979
George G. Jackson Visiting Professor Award, Infectious Diseases Society of America	1990
Elected Councilor, Infectious Diseases Society of America	1998
Bristol Myers Squibb Unrestricted Laboratory Research Award in Infectious Diseases 2000 - 2005	
Honorary Degree, Pomona College, 2002, D.Sc	

ONGOING RESPEARCH SUPPORT

POI AI37194-07 (Edwards)

01/01/95 – 03/31/05

NIH/NIAID

Candida Adherence Mycology Research Unit

The major goal of this project is to form a Candida Adherence Mycology Research Unit by bringing together a group of experienced investigators with long-standing expertise in the area of cell-to-cell recognition, to advance the field of candidal adherence into a new level of understanding that would not otherwise be possible. Projects include the transformation of candidal genomic DNA into *S. cerevisiae*.

Role: PI

5 R01 AI19990-17 (Edwards)

08/01/84 – 07/31/03 (renewal pending)

NIH/National Institutes of Allergy

Candida Adherence and Penetration of Vascular Endothelium

The major goal of this project is to devise strategies to improve host defense against Candida, to investigate how IFN-gamma induces endothelial cells to resist candidal damage, to develop strategies to increase the combined capacity of neutrophils and endothelial cells to kill Candida by priming both cell types with immunomodulators, and to clone the adherence genes of Candida in *Saccharomyces cerevisiae*.

Role: PI

Bristol – Myers Squibb Company (Edwards)

07/01/90 – 06/30/05

Unrestricted Grant for Infectious Diseases Research

This grant is to be used for the support of studies in the field of infectious diseases research under the direction of John Edwards, Jr., M.D. Two are awarded internationally per year. They are unconditionally unrestricted.

Role: PI

5 RO1 AI16567-20 (—)

06/15/01 – 04/30/06

NIH/NIAID

(Subcontract from the University of Minnesota)

Establishment of a Genetic System in *Candida Albicans*

The research will investigate whether *C. albicans* can mate in an animal host and whether mating plays an important role in the life cycle of the microbe including colonization and the process causing infection.

Role: Co-Investigator

Gilead Sciences, Inc. (—)

03/31/01 – 06/30/03

AmBisome versus Amphotericin B in the Treatment of Zygomycosis

To compare the efficacy of using high doses of Ambisome to a traditional dose of amphotericin B in treating infection caused by Rhizopus oryzae using the murine model of hematogenously disseminated infections.

Role: Co-Investigator

Merck & Co., Inc. ()

04/24/01 – 04/23/03

Casopofungin Acetate versus Amphotericin B in the Treatment of Zygomycosis

To compare the efficacy of caspofungin acetate and amphotericin B in treating infections caused by the microbe Rhizopus oryzae.

Role: Co-Investigator

Elan Pharmaceuticals, Inc. ()

06/21/02 – 06/30/04

Treatment of Murine Experimental Mucormycosis by Using a Combination of Abelcet and Caspofungin Acetate. This study will: 1) Study the toxicity of ABLC, 2) Test the ability of 4 different doses of ABLC that cause the least protective effect against hematogenesis, 3) Study the effect of combination studies of ABLC and caspofungin acetate on hematogenously disseminated mucormycosis infection in diabetic mice, 4) Study tissue fungal burden and clearance rates of mice treated with the combination regimen.

Role: Co-Investigator

PENDING

RFP Number: NIH-NIAID-DMID-03/09

05/05/03 – 05/04/2010

Subcontract Principal Investigator: ()

University of Texas Health Science Center at San Antonio

New Animal Models for Tuberculosis (TB) and Invasive Aspergillosis (IA).

BIBLIOGRAPHY
John E. Edwards, Jr., M.D.

RESEARCH PAPERS (PEER REVIEWED)

A. Research Papers – Peer Reviewed

1. Goldin RH, AW Chow, JE Edwards, Jr, JS Louie, LB Guze: Sternoarticular septic arthritis in heroin users. *N Engl J Med* 288:616, 1973.
2. Edwards JE, Jr, RY Foos, JZ Montgomerie, LB Guze: Ocular manifestations of *Candida* septicemia. Review of seventy-six cases of hematogenous *Candida* endophthalmitis. *Medicine* 53:47, 1974.
3. Edwards JE, Jr, SB Turkel, HA Elder, RW Rand, LB Guze: Hematogenous *Candida* osteomyelitis. Report of three cases and review of the literature. *Am J Med* 59:89, 1975.
4. Edwards JE, Jr, JZ Montgomerie, RY Foos, V Shaw, LB Guze: Experimental hematogenous *Candida albicans* endophthalmitis. *J Infect Dis* 131:649, 1975.
5. Montgomerie JZ, JE Edwards, Jr, LB Guze: Synergism of Amphotericin B and 5-fluorocytosine for *Candida* species. *J Infect Dis* 132:82, 1975.
6. Bayer AS, JE Edwards, Jr, LB Guze: *Candida* meningitis. Report of seven cases and review of the English literature. *Medicine* 55:477, 1976.
7. Oill P, JZ Montgomerie, WS Cryan, JE Edwards, Jr: Infectious Disease Emergencies. Part V: Patients presenting with localized infection. *West J Med* 126:196, 1977.
8. Edwards JE, Jr, JZ Montgomerie, K Ishida, JO Morrison, LB Guze: Experimental hematogenous *Candida* endophthalmitis. Species variation in ocular pathogenicity. *J Infect Dis* 135:294, 1977.
9. Nilsson-Ehle I, TT Yoshikawa, JE Edwards, Jr, MC Schotz, LB Guze: Quantitation of Amphotericin B with use of high-pressure liquid chromatography. *J Infect Dis* 135:414, 1977.
10. Cohen M, JE Edwards, Jr, TJ Hensley, LB Guze: Experimental hematogenous *Candida albicans* ophthalmitis: electron microscopy. *Invest Ophthalmol and Vis Sci* 16:498, 1977.
11. Montgomerie JZ, JE Edwards, Jr: Association of infection due to *Candida albicans* with intravenous hyperalimentation. *J Infect Dis* 137:197, 1978.

12. Edwards JE, Jr, RI Lehrer, ER Steihm, TJ Fischer, LS Young: Severe Candida infections: Clinical perspectives, immune defense mechanisms, and current concepts of therapy. (UCLA Interdepartmental Conference). Ann Intern Med 88:91, 1978.
 13. Henderson DK, JE Edwards, Jr, K Ishida, LB Guze: Experimental hematogenous Candida endophthalmitis: Diagnostic approaches. Infect Immun 23:858, 1979.
 14. Edwards JE, Jr, DB Tillman, HE Pitchon, ME Miller: Infection in diabetes. West J Med 130:515, 1979.
 15. Edwards JE, Jr, WA Combs, LB Guze: Malignant Pseudomonas external otitis. West J Med 131:247, 1979.
 16. Bayer AS, JE Edwards, Jr, LB Guze: Experimental intraabdominal candidiasis in rabbits. Macroscopic, microscopic and cultural natural history. Digestion 20:365, 1980.
 17. Henderson DK, LB Hockey, LJ Vukalcic, JE Edwards, Jr: Effect of immunosuppression on the development of experimental hematogenous Candida endophthalmitis. Infect and Immun 27:628, 1980.
 18. Edwards JE, Jr, JO Morrison, DK Henderson, JZ Montgomerie: Combined effect of amphotericin B and rifampin on Candida species. Antimicrob Agents Chemother 17:484, 1980.
 19. Yoshikawa TT, NK Fujita, JE Edwards, Jr, V Grinnell, R Feldman: Management of central nervous system cryptococcosis. West J Med 132:123, 1980.
 20. Lehrer RI, DH Howard, PS Sypherd, JE Edwards, Jr, GP Segal, DJ Winston: Mucormycosis. Ann Intern Med 93:93, 1980.
 21. Henderson DK, JE Edwards, Jr, JZ Montgomerie: Hematogenous Candida endophthalmitis in patients receiving parenteral hyperalimentation fluids. J Infect Dis 143:655, 1981.
 22. Fujita NK, M Reynard, F Sapico, LB Guze, JE Edwards, Jr: Cryptococcal intracerebral mass lesions - Role of CT and non-surgical therapy. Ann Intern Med 94:382, 1981.
 23. Bayer AS, JE Edwards, Jr, LB Guze: Experimental intraabdominal candidiasis in rabbits - therapy with low total dose intravenous amphotericin B. Antimicrob Agents Chemother 19:179, 1981.
 24. Fujita NK, JE Edwards, Jr: Combined in vitro effect of amphotericin B and rifampin on cryptococcus. Antimicrob Agents Chemother 19:196, 1981.
 25. Seidel JS, P Harmatz, A Cohen, G Visvesvera, JE Edwards, Jr, J Turner: Successful treatment of primary meningoencephalitis. N Engl J Med 306:346, 1982.
-

26. Fujita NK, DK Henderson, LJ Hockey, LB Guze, JE Edwards, Jr: Comparative ocular pathogenicity of Cryptococcus neoformans, Candida glabrata, and Aspergillus fumigatus in the rabbit. Invest Ophthalmol Vis Sci 22:410, 1982.
27. Hockey LJ, NK Fujita, TR Gibson, D Rotrosen, JZ Montgomerie, JE Edwards Jr: Detection of fungemia obscured by concomitant bacteremia: In vitro and in vivo studies. J Clin Microbiol 16:1080, 1982.
28. Rotrosen D, TR Gibson JE Edwards, Jr: Adherence of Candida to intravenous catheters. J Infect Dis 147:594, 1983.
29. Fujita NK, J Hukkanen, JE Edwards, Jr: Experimental hematogenous endophthalmitis due to Cryptococcus neoformans. Invest Ophthalmol 24:368, 1983.
30. Greenberg M, S Lippman, V Grinnell, MF Coleman, JE Edwards, Jr: Computed tomography in orbital mucor. Case report and review of the literature. West J Med 143:102, 1985.
31. Rotrosen D, JE Edwards, Jr, J Moore, J Adler, AH Cohen, I Green: Pathogenesis of hematogenous candidiasis: Adherence of Candida species to vascular endothelium and mechanisms of endothelial cell invasion. J Infect Dis 152:1264, 1985.
32. Rotrosen D, Calderone R, Edwards JE, Jr: Adherence of Candida to biological surfaces and prosthetic materials. Rev Infect Dis 8:73, 1986.
33. Edwards JE, Jr, T Gaither, J O'Shea, D Rotrosen, T Lawly, S Wright, M Frank, I Green: Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J Immunol 137:3577, 1986.
34. Filler SG, LC Der, CL Mayer, PD Christenson, JE Edwards, Jr: An enzyme-linked immunosorbent assay for quantifying adherence of Candida to human vascular endothelium. J Infect Dis 156:561, 1987.
35. Edwards JE, Jr, DR Rotrosen, JW Fontaine, CC Haudenschild, RD Diamond: Neutrophil-mediated protection of cultured human vascular endothelial cells from damage by growing Candida albicans hyphae. Blood 69:1450, 1987.
36. Effros RM, P Dodek, JE Edwards Jr: Estimation of endothelial receptor sites with the mean transit time approach. Ann Biomed Eng 15:187, 1987.
37. Crandall M, JE Edwards, Jr: Segregation of proteinase negative mutants from heterozygous Candida albicans. J Gen Bacteriol, J. Gen. Microbiol. 133:2817-2824, 1987.

38. Effros RM, K Taki, P Dodek, JE Edwards, Jr, A Huscuk, P Silverman, J Hukkanen: Exchange of labeled bicarbonate and carbon dioxide with red cells suspended in an elutriator. In press, J Appl. Physiol. February 1988.
 39. Fish DG, Ampel NM, Galgiani JN, Dolas CL, Kelly PC, Johnson CH, Pappagianis D, Edwards JE, Jr, Wasserman RB, Clark RJ, et al: Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine 69:384-391, 1990.
 40. Mayer CL, Diamond RD, Edwards JE, Jr: Recognition of binding sites on Candida albicans by monoclonal antibodies to human leukocyte antigens. Infect Immun 58:3765-3769, 1990.
 41. Dodek PM, Minshell DK, Edwards JE, Jr, Effros RM: A new simulation of the interaction between neutrophils and endothelial cells. Microvascular Research 39:105-119, 1990.
 42. Filler SG, Crislip MA, Mayer CL, Edwards JE, Jr: Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits. Antimicrob Agents Chemother 35:288-292, 1991.
 43. Filler SG, Ibe BO, Luckett PM, Raj JU, Edwards JE, Jr: Candida stimulates endothelial cell eicosanoid production. J Infect Dis 164:928-935, 1991.
 44. Mayer CL, Filler SG, Edwards JE, Jr: Candida albicans adherence to endothelial cells. Microvasc Res 43:218-226, 1992.
 45. Edwards JE, Jr, Mayer CL, Filler SG, Wadsworth E, Calderone RA: Cell extracts of Candida albicans block adherence of the organisms to endothelial cells. Infect Immun 60:3087-3091, 1992.
 46. Ghannoum MA, Filler SG, Ibrahim AS, Fu Y, Edwards JE, Jr: Modulation of the interactions of Candida albicans and endothelial cells by selected antifungal agents. J Antimicrob Agents Chemother 36:2239-2244, 1992.
 47. Ghannoum MA, Ibrahim AS, Fu Y, Shafiq MC, Edwards JE, Jr, Criddle RS. 1992. Susceptibility testing of Cryptococcus neoformans: A microdilution technique. J. Clin. Microbiol. 30:2881-2886.
 48. Ibrahim AS, Ghannoum MA, Filler SG, Edwards JE, Jr: Interferon gamma protects endothelial cells from damage by Candida albicans. J Infect Dis 107:1467-1470, 1993.
 49. Yeaman MR, Ibrahim AS, Edwards JE, Jr, Bayer AS, Ghannoum MA: Thrombin-induced platelet microbicidal protein is fungicidal in vivo. Antimicrob Agents Chemother 37:546-553, 1993.
-

50. Alcouloumre MS, Ghannoum MA, Ibrahim AS, Selsted ME, Edwards JE, Jr: Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro. *Antimicrob Agents Chemother*, 37:2628-2632, 1993.
51. Filler SG, Ibe BO, Ibrahim AS, Ghannoum MA, Raj JU, Edwards JE, Jr: Mechanisms by which Candida albicans induces endothelial cell prostaglandin synthesis. *Infect Immun* 62:1064-1069, 1994.
52. Ghannoum MA, Spellberg BA, Ibrahim AS, Currie B, Spitzer E, Edwards JE, Jr, Ritchie J and Casadevall A. 1994. Cryptococcus neoformans sterol composition in the presence and absence of fluconazole. *Antimicrob. Agents Chemother*. 38:2029-2033, 1994.
53. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Jr, Washburn RG, Scheld WM, Karchmer AW, Dine AP, et al. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. *N. Eng. J. Med*. 331:1325-1330.
54. Witt MD, Lewis RJ, Larsen RA, Milefchik EN, Leal MAE, Haubrich RH, Ritchie JA, Edwards JE, and Ghannoum MA. 1996. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. *Clin. Infect. Dis*. 22:322-328.
55. Ibrahim AS, Mirbod F, Filler SG, Banno Y, Cole GT, Kitajima Y, Edwards JE, Jr, Nozawa Y, Ghannoum MA. 1995. Evidence implicating phospholipase as a virulence factor in Candida albicans. *Infect. Immun*. 63:1993-1998.
56. Ibrahim AS, Filler SG, Alcouloumre MS, Kozel TR, Edwards JE, Jr, Ghannoum MA. 1995. Adherence to and damage of endothelial cells by Cryptococcus neoformans: comparison between acapsular and encapsulated strains. *Infect. Immun*. 63:4368-4374.
57. Currie B, Sanati H, Ibrahim AS, Edwards JE, Jr, Casadevall A, Ghannoum MA. Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. *Antimicrob. Agents Chemother*. 1995;39: 1934-1937.
58. Radner AB, Witt MD, Edwards JE, Jr. Acute invasive rhinocerebral zygomycosis in an otherwise healthy patient: Case report and review. *Clin. Infect. Dis*. 1995; 20:163-166.
59. Ghannoum MA, Fu Y, Ibrahim AS, Mortara LA, Shafiq MC, Edwards JE, Jr, Criddle RS. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. *Antimicrob. Agents Chemother*. 1995;39:2459-2465.
60. Rex JH, Bennett JE, Sugar AM, Pappas PG, Serody J, Edwards JE, Washburn RG. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. *Clin. Infect. Dis*. 21:994-996. 1995.

61. Yeaman MR, Soldan SS, Ghannoum MA, Edwards JE, Jr, Filler SG, Bayer AS. Resistance to platelet microbicidal protein results in increased severity of experimental Candida albicans endocarditis. Infect. Immun. 1996; 64:1379-84.
62. Filler SG, Pfunder AS, Spellberg BJ, Spellberg JP, Edwards JE, Jr. Candida albicans stimulate cytokine production and leukocyte adhesion molecule expression by endothelial cells. Infect. Immun. 64:2609-2617, 1996.
63. Fratti RA, Ghannoum MA, Edwards JE, Jr, Filler SG. Gamma interferon protects endothelial cell injury caused by Candida albicans by inhibiting endothelial cell phagocytosis. Infect. Immun. 64:4714-4718, 1996.
64. Edwards JE, Jr., et al. International Conference for the Development of a Consensus on the Management of Severe Candida Infections. Clinical Infectious Diseases, 25:43-59, 1997.
65. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Jr, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clinical Infectious Diseases, 1997. 25(3): p. 551-73.
66. Fratti RA, Belanger PH, Ghannoum MA, Edwards JE, Jr, Filler SG. Endothelial cell injury caused by Candida albicans is dependent on iron. Infect. Immun., 66:191-196, 1998.
66. Fu Y, Spellberg BJ, et al. Cloning and characterization of CAD1/AAF1, a gene from Candida albicans that induces adherence to endothelial cells after expression in Saccharomyces cerevisiae. Infect. Immun. 1998; 66:2078-84.
67. Fu Y, Filler SG, Spellberg BJ, Fonzi W, Ibrahim AS, Kanbe T, Ghannoum MA, Edwards JE Jr. Cloning and characterization of CAD1/AAF1, a gene from Candida albicans that induces adherence to endothelium when expressed in Saccharomyces cerevisiae. Infect Immun 1998;66:2078-84.
68. Ibrahim AS, Filler SG, Sanglard D, Edwards JE, Jr, Hube B. Secreted aspartyl proteinases and interactions of Candida albicans with human endothelial cells. Infect. Immun. 66: 3003-3005, 1998.
69. Fu Y, Rieg G, Fonzi WA, Belanger PH, Edwards JE, Jr, Filler SG. Expression of the Candida albicans gene ALS1 in Saccharomyces cerevisiae induces adherence to endothelial and epithelial cells. Infect. Immun. 66:1783-1786, 1998.
70. Ibrahim AS, Filler SG, Sanglard D, Edwards JE Jr, Hube B. Secreted aspartyl proteinases and the interactions of Candida albicans with endothelial cells and neutrophils. Infect Immun 1998;66:3003-5.

71. Pfaller MA, Messer SA, Houston A, Rangel-Frausto MS, Wiblin T, Blumberg HM, Edwards JE, Jr, Jarvis W, Martin MA, Neu HC, Saiman L, Patterson JE, Dibb JC, Rolden CM, Rinaldi MG, Wenzel RP. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of *Candida* species. *Diagnostic Microbiology and Infectious Disease* 1998; 31:289-96.
72. Marco F, Lockhart SR, Pfaller MA, Pujol C, Rangel-Frausto MS, Wiblin T, Blumberg HM, Edwards JE, Jarvis W, Saiman L, Patterson JE, Rinaldi MG, Wenzel RP, The NEMIS Study Group, Soll DR. Elucidating the Origins of Nosocomial Infections with *Candida albicans* by DNA Fingerprinting with the Complex Probe Ca3. *J Clin Microb*, 1999; 37: 2817-28.
73. Rieg G, Fu Y, Ibrahim AS, Zhou X, Filler SG, Edwards JE. Unanticipated Heterogeneity in Growth Rate and Virulence among *Candida albicans* AAF1 Null Mutants. *Infect Immun* 1999; 67: 3193-98.
74. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to *Candida* species in seven surgical intensive care units and six neonatal intensive care units. *Clinical Infect. Dis.*, 1999; 29:253-8.
75. Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. *Clinical Infect. Dis.*, 1995; 21:994-6.
76. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. *Infectious Diseases Society of America. Clinical Infect. Dis.*, 2000; 30:662-78.
77. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. *Pediatric Infectious Disease Journal* 2000; 19:319-24.
78. Clemons KV, Calich VL, Burger E, Filler SG, Graziutti M, Murphy J, Roilides E, Campa A, Dias MR, Edwards JE Jr, Fu Y, Fernandes-Bordignon G, Ibrahim A, Katsifa H, Lamaignere CG, Meloni-Bruneri LH, Rex J, Savary CA, Xidieh C. Pathogenesis I: interactions of host cells and fungi. *Med Mycol.* 2000; 38 Suppl 1:99-111.
79. Davis D, Edwards JE Jr, Mitchell AP, Ibrahim AS. *Candida albicans* RIM101 pH response pathway is required for host-pathogen interactions. *Infect Immun.* 2000 Oct;68(10):5953-9.
80. Miller LG, Hajjeh RA, Edwards JE Jr. Estimating the cost of nosocomial candidemia in the United States. *Clin Infect Dis.* 2001 Apr 1;32(7):1110.

81. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001 Jul 15;33(2):177-86.
82. Saiman L, Ludington E, Dawson JD, Patterson JE, Rangel-Frausto S, Wiblin RT, Blumberg HM, Pfaller M, Rinaldi M, Edwards JE, Wenzel RP, Jarvis W. Risk factors for *Candida* species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J. 2001 Dec;20(12):1119-24.
83. Tsuchimori N, Sharkey LL, Fonzi WA, French SW, Edwards JE, Jr, Filler SG. Reduced virulence of HWP1-deficient mutants of *Candida albicans* and their interactions with host cells. Infection and Immunity 2000; 68:1997-2002.
84. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Steven DA, Walsh TJ. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002 Jan 1;34(1): 7-14.
85. Fu Y, Ibrahim AS, Sheppard DC, Chen Y-C, French SW, Cutler JE, Filler SG, Edwards, JE, Jr. *Candida albicans* Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol. Microbiol 2002, Apr 44 (1) 61-72.
86. Cannom, R., French, S., Johnston, D., Edwards, Jr., J., Filler, SG. *Candida albicans* Stimulates Local Expression of Leukocyte Adhesion Molecules and Cytokines n Vivo. J Infect Dis 186:389-96, 2002.
87. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vasquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu TC, Panzer H, Rosenstein RB, Booth J. A Randomized and Blinded Multicenter Trial of High-Dose Fluconazole plus Placebo versus Fluconazole plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects. Clin Infect Dis. 2003 May15;36(10): 1221-8

RESEARCH PAPERS (NON-PEER REVIEWED)

D. Research Papers – Non-Peer Reviewed

88. Edwards JE, Jr: Update on Systemic Fungal Infections. Part 1. Hospital Physician 18:14, 1982.

89. Edwards JE, Jr: Update on Systemic Fungal Infections. Part 2. Hospital Physician 19:22, 1983.
90. Bennett JE, JE Edwards, Jr, D Drutz, JS Remington: Controversies in the management of Candida infections. Academy Professional Publication Services, 1986.
91. Edwards JE, Jr, D Drutz, JE Bennett, JS Remington: Disseminated candidiasis in cancer and postoperative patients. Academy Professional Publication Services, 1986.
92. Swerdloff JN, Filler SG, Edwards JE, Jr.: Management of the patient with candidemia and a central venous catheter. Clinic Guide to Fungal Infections, 1994;5:3-7.
93. Edwards JE, Jr.: Treatment of Serious Candidal Infections: Selected Considerations. MDvista Journal, 2000.

CHAPTERS

1. Edwards JE, Jr: Candida Infections. In: Principles and Practice of Infectious Diseases, 1st edition, Chapter 211. Mandell GL, Douglas RG, Jr, Bennett JE (eds), John Wiley & Sons, Inc., New York, New York, 1979.
2. Edwards JE, Jr: Mucocutaneous Fungal Infections. In: Infectious Diseases - Diagnosis and Management. Yoshikawa TT, Chow AW, Guze LB (eds), Houghton-Mifflin Publishers, Boston, Massachusetts, 1980.
3. Edwards JE, Jr: Systemic Mycoses. In: Infectious Diseases Diagnosis and Management. Yoshikawa TT, Chow A, Guze LB (eds), Houghton-Mifflin Publishers, Boston, Massachusetts, 1980.
4. Edwards JE, Jr: Antibiotic and Hepatic Disease. In: Infectious Diseases - Diagnosis and Management. Yoshikawa TT, Chow AW, Guze LB (eds), Houghton-Mifflin Publishers, Boston, Massachusetts, 1980.
5. Edwards JE, Jr: Infections of the eye. In: Infectious Diseases Diagnosis and Management. Yoshikawa TT, Chow AW, Guze LB (eds), Houghton-Mifflin Publishers, Boston, Massachusetts, 1980.
6. Edwards JE, Jr: Thrush of the Mouth and Esophagus. In: International Textbook of Medicine. Volume II. Medical Microbiology and Infectious Diseases, Chapter 88, Abraham I. Braude, (ed), W.B. Saunders Co., Philadelphia, PA, 1981.
7. Edwards JE, Jr: Fungemia. In: International Textbook of Medicine. Volume II. Medical Microbiology and Infectious Diseases, Chapter 176. Abraham I. Braude, (ed), W.B. Saunders, Co., Philadelphia, PA, 1981.

8. Edwards JE, Jr: Moniliasis of the Skin. In: International Textbook of Medicine. Volume II. Medical Microbiology and Infectious Diseases, Chapter 194. Abraham I. Braude, (ed), W.B. Saunders, Co., Philadelphia, PA, 1981.
9. Edwards JE, Jr: Candida Endophthalmitis. In: Current Clinical Concepts in Infectious Diseases. M.N. Schwartz & J.S. Remington (eds), McGraw and Hill, New York, New York, 1982.
10. Edwards JE, Jr: Zygomycosis. In: Infectious Diseases. Hoeprich PD (ed), Harper and Row, Third Edition, 1983.
11. Beck CK, JE Edwards, Jr: Infection in Renal Transplantation. In: Current Therapy in Nephrology and Hypertension. R.G. Glasscock (ed), B.C. Decker, Canada, 1984.
12. Edwards JE, Jr: Candida Infections. In: Principles and Practice of Infectious Diseases, 2nd edition, Chapter 211. Mandell GL, Douglas RG, Jr, Bennett JE (eds), John Wiley & Sons, Inc., New York, New York, 1985.
13. Rotrosen D, JE Edwards, Jr: Opportunistic Mycoses. In: Current Diagnosis. Rex B. Conn (ed), W.B. Saunders, Co., Philadelphia, PA, 1985.
14. Edwards JE, Jr: Candida Endophthalmitis. In: Candidiasis, G.P. Bodey and V. Fainstein (eds), Raven Press, New York, New York, 1985.
15. Beck CK, JE Edwards, Jr: Infection in Renal Transplantation. In: Current Therapy in Nephrology and Hypertension. R.G. Glasscock (eds), B.C. Decker, Canada, 1986.
16. Edwards JE, Jr: Thrush of the Mouth and Esophagus. In: International Textbook of Medicine, Volume II. Medical Microbiology and Infectious Diseases, Chapter 88. Abraham I. Braude, (ed), W.B. Saunders Co., Philadelphia, PA, 1986.
17. Edwards JE, Jr: Fungemia. In: International Textbook of Medicine. Volume II. Medical Microbiology and Infectious Diseases, Chapter 176. Abraham I. Braude, (ed), W.B. Saunders Co., Philadelphia, PA. Revised 1986.
18. Edwards JE, Jr: Moniliasis of the Skin. In: International Textbook of Medicine. Volume II. Medical Microbiology and Infectious Diseases, Chapter 194. Abraham I. Braude, (ed), W. Saunders Co., Philadelphia, PA, 1986.
19. Edwards JE, Jr: Candida Infections. In: Principles and Practice of Infectious Diseases, 3rd edition, Chapter 235. Mandell GL, Douglas RD, Jr., Bennett (eds). John Wiley & Sons Inc., New York, NY, 1989.
20. Crislip MA, Edwards JE, Jr: Candidiasis. Infect Dis Clin N Amer 3:103-133, 1989.

21. Edwards JE, Jr: Zygomycosis. In: Infectious Diseases. Hoeprich PD (ed), Harper and Row, Third Edition, 1989.
22. Edwards JE, Jr: Candida Species. In: Mandell GL, Douglas RG, Jr, Bennett JE, (eds). Principles and Practice of Infectious Diseases. 3rd ed. New York: Churchill Livingstone Inc. 1990:1943-1955.
23. Edwards JE, Jr, Mayer CL: Adherence of Candida albicans to mammalian cells. In: Ayoub EM, Cassell GH, Branche WC, Jr, Henry TJ (eds). Microbial Determinants of Virulence and Host Response. Washington, D.C. American Society for Microbiology, 1990:179-194.
24. Witt MD, Edwards JE, Jr: Pancreatic abscess and infected pancreatic pseudocyst: Diagnosis and treatment. In: JS Remington, MN Swartz (eds) Current Clinical Topics in Infectious Diseases. Volume 12. Boston: Blackwell Scientific Publications, Inc. 1991.
25. Rotrosen D, Edwards JE, Jr: Opportunistic Mycoses. In: Current Diagnosis. RB Conn (ed). WB Saunders Co., Philadelphia, PA. 1991:263-269.
26. Edwards JE, Jr: Opportunistic fungal infections. In: Kelly WN et al, (eds). Textbook of Internal Medicine. 2nd ed, JB Lippincott Company, New York 1992:1458-1462.
27. Crislip MA, Edwards JE, Jr: Candida albicans and related species. In: Gorbach SL, Bartlett JG, Blackow NR (eds). Infectious Diseases. Philadelphia: WB Saunders Company 1992:1887-1895.
28. Morris MI, Edwards JE, Jr: Fungal infections of the skin. In: Infectious Diseases. SL Gorbach, JG Bartlett, NR Blacklow (eds). WB Saunders Co., Philadelphia, PA 1992:1079-1088.
29. Morris MI, Edwards JE, Jr: The dematiaceae. In: Infectious Diseases. SL Gorbach, JG Bartlett, NR Blacklow (eds). WB Saunders Co., Philadelphia, PA 1992:1937-1946.
30. Edwards JE, Jr: Human complement receptor-like molecules on Candida. In: Bennett JE, Hay RJ, Peterson PK (eds). New Strategies in Fungal Disease. Edinburgh: Churchill Livingstone, 1992:54-62.
31. Moyer D, Edwards JE, Jr: Candida endophthalmitis. In: Bodey GP, Anaissie E (eds). Candidiasis. New York, Raven Press, 1992:331-335.
32. Moyer D, Edwards JE, Jr: Fungal Endocarditis. In: Infective Endocarditis. Kaye D (ed). New York, Raven Press, 1992:299-312.
33. Beck K, Edwards JE, Jr: Infection in the Renal Transplant Patient. In: Current Therapy in Nephrology and Hypertension. RG Glasscock (ed). Mosby Year Book, 1992:428-435.

34. Witt, MD, Edwards JE, Jr: Pancreatic abscess and infected pancreatic pseudocyst: Diagnosis and Treatment. In: Current Clinical Topics in Infectious Diseases. 1992;12:111-137.
35. Anaissie E, Edwards JE, Jr, Bodey GP: Terminology for Infections with Candida Species. In: Bodey GP and Anaissie E (eds). Candidiasis. New York, Raven Press, 1993:407-408.
36. Filler SG, Edwards JE, Jr. Chronic Mucocutaneous Candidiasis. In: Fungal Infections and Immune Response. Friedman Hm Murphy J, Bendinelli M (eds). Plenum Press, New York. 1993;117-134.
37. Filler SG, Edwards JE, Jr: Chronic mucocutaneous candidiasis. In: Fungal Infections and Immune Response. H Friedman, J Murphy, M Bendinelli (eds). Plenum Press, New York. 1993:117-134.
38. Edwards JE, Jr: Candida Infections. In: Principles and Practice of Infectious Diseases, 3rd edition, Chapter 235. Mandell GL, Douglas RG, Jr., Bennett J (eds). John Wiley & Sons Inc., New York, NY in press, 1994.
39. Edwards JE, Jr: Zygomycosis. In: Infectious Diseases. Hoeprich PD (ed). Harper and Row, 3rd Edition, in press, 1994.
40. Edwards JE, Jr: Infections caused by Candida, Actinomyces, and Nocardia. In: Internal Medicine. Chapter 278. Stein JH (Ed.in Chief). Mosby, St. Louis, 4th edition, 1994.
41. Filler SG, Edwards JE, Jr. When and How To Treat Serious Candidal Infections: Concepts and Controversies. In: Current Clinical Topics in Infectious Diseases, Vol. 15. Remington JS, Swartz MN (eds). Blackwell Scientific Publications. 1995;1-18.
42. Edwards, JE, Jr. Opportunistic Fungal Infections. In: Textbook of Internal Medicine, Kelly WN (editor-in-Chief). J.B. Lippincott, 3rd edition. 1995.
43. Ghannoum MA, Edwards KE, Edwards JE, Jr: Pathogenesis of fungal infections. In: Bailliere's Clinical Infectious Diseases, Invasive Fungal Infections in Cancer Patients. Chapter 1. Meunier F (ed). Bailliere Tindall, London, 1995.
44. Pettit TH, Edwards JE, Jr, Purdy EP, Bullock JD: Endogenous Fungal Endophthalmitis. In: Ocular Infection and Immunity. Chapter 91. Pepose JS, Holland GN, Wilhelmus KR (eds). Mosby, St. Louis, 1996.
45. Edwards JE, Jr: Opportunistic Fungal Infections. In: Textbook of Internal Medicine. Chapter 304. Kelly WN (ed in chief). Lippincott-Raven, Philadelphia, 3rd edition, 1997.
46. Edwards JE, Jr: Infections caused by Candida, Actinomyces, and Nocardia. In: Internal Medicine. 5th Edition. Chapter 277. Stein JH (ed. in chief). Mosby, Inc., 1998.

47. Pappas PG, Edwards JE, Jr. Antifungal Drugs. In: Clinical Infectious Diseases. Chapter 41. Root, R (editor-in-chief). Oxford University Press, Inc., 1999.
48. Pappas PG, Edwards JE, Jr. Selection of Antifungal Drugs for Deep Mycoses. In: Clinical Infectious Diseases. Chapter 42. Root, R (editor-in-chief). Oxford University Press, Inc. 1999.
49. Edwards JE, Jr., Pappas PG. Fungi and Fungal Diseases. In: Clinical Infectious Diseases. Chapter 6. Root, R (editor-in-chief). Oxford University Press, Inc., 1999.
50. Edwards JE, Jr: *Candida* Species. In: Principles and Practice of Infectious Diseases, 5th edition. Chapter 247. Mandell GL, Bennett JE, Dolin R (eds). Churchill Livingstone, 2000
51. Edwards JE, Jr: Management of Severe Candidal Infections: Integration and Review of Current Guidelines for Treatment and Prevention. In: Current Clinical Topics in Infectious Diseases, 21st edition. Remington JS, Swartz MN (eds.) Iowa State University Press, 2001:135-147.
52. Edwards JE, Jr: Opportunistic Fungal Infections. In: Kelley's Textbook of Internal Medicine, 4th edition. Humes DH (ed).
53. Edwards JE, Jr: Fungal Infections. In: The Merck Manual of Medical Information – Home Edition, Edition 2.
54. Spellberg B, Edwards JE. The Pathophysiology and Treatment of *Candida* Sepsis. In: Current Infectious Diseases Rep 2002:387-399

LETTERS TO THE EDITOR

1. Montgomerie JC, DK Henderson, JE Edwards, Jr: In reply to letter by Drs. P.J. Pockroff and H. Wilberman regarding parental nutrition associated with candidiasis. Correspondence Section. *J Infect Dis* 146:592, 1982.
2. Miller, L.G., Hajjeh, R.A., Edwards, J.E., Jr. Estimating the cost of nosocomial candidemia in the United States. *Clin Inf. Dis.* 32; 1110, 2001.
3. Hopkins JT, Ingersoll CD, Krause BA, Edwards JE, Jr. Cordova ML. Reply to Dr. Chandrasekar and Drs. Marr and Boeckh. *Clin. Infect. Dis.* 518-9, 2001
4. Gilbert DN, Edwards JE, Jr. Is there hope for the prevention of future antimicrobial shortages? *Clin. Infect. Dis.* 216-7, 2002
5. Spellberg B, Rieg G, Bayer A, Edwards JE, Jr. Lack of cross-hepatotoxicity between fluconazole and voriconazole. *Clin. Infect. Dis.* 1091-3, 2003

REVIEWS

1. Edwards JE, Jr: Disseminated Candidiasis: AIDS in Clinical Diagnosis. Antibiotic Therapy 3:1, 1977.
2. Edwards JE, Jr: Diagnosis and Management of Candida Infections. Infectious Diseases Newsletter. Hoeprich PD (ed). Elsevier. 1986.
3. Edwards JE, Jr: Systemic symptoms from Candida in the gut: Real or imaginary? Bull NY Acad. Med. 64:544, 1988.
4. Edwards JE, Jr, Filler SG: Current strategies for treating invasive candidiasis with emphasis on infections in non-neutropenic patients. Clinical Infect. Dis. 14(Suppl 1):S106-13, 1992.
5. Ghannoum MA, Edwards JE, Jr: Candida adherence to epithelial cells. J. Mycol. Med. 2:10-13, 1992.
6. Swerdloff JN, Filler SG, Edwards JE, Jr: Severe Candida infections in neutropenic patients. Clin. Infect. Dis. 17(suppl):S457-67, 1993.
7. Calderone R, Diamond R, Senet JM, Warmington J, Filler S, Edwards JE, Jr.: Host cell-fungal cell interactions. J. Med. Vet. Mycol. 32(suppl)1:151-68, 1994.
8. Edwards JE Jr, Bodey GP, Bowden RA, Buchner T, de Pauw BE, Filler SG, Ghannoum MA, Glauser M, Herbrecht R, Kauffman CA, Kohno S, Martino P, Meunier F, Mori T, Pfaller MA, Rex JH, Rogers TR, Rubin RH, Solomkin J, Viscoli C, Walsh TJ, White M. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997;25:43-59.
9. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE Jr. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000;30:662-78.
10. Clemons KV, Calich VL, Burger E, Filler SG, Graziutti M, Murphy J, Roilides E, Campa A, Dias MR, Edwards JE, Jr, Fu Y, Fernandes- Bordignon G, Ibrahim A, Katsifa H, Lamaignere CG, Meloni- Bruneri LH, Rex J, Savary CA, Xidieh C. Pathogenesis I: interactions of host cells and fungi. Med. Mycol 2000;38 Suppl 1:99-111
11. Spellberg B, Edwards, JE, Jr. Type 1/Type 2 Immunity in Infectious Diseases. Clinical Infectious Diseases 2001; 32:76-102.

12. Spellberg B, Edwards JE. The Pathophysiology and Treatment of *Candida* Sepsis. In: Current Infectious Diseases Rep 2002:387-399

EDITORIALS

1. Edwards JE, Jr: Invasive *Candida* infections. Evolution of a fungal pathogen. (editorial). *N Engl J Med* 324:1060-1062, 1991.
2. Edwards JE: Editorial Response: Should all patients with candidemia be treated with antifungal agents? *Clin Infect Dis* 15:422-423, 1992.
3. Edwards, J.E., Jr. and K.E. Edwards, Reflections on studies in developing countries [editorial; comment]. *Clinical Infectious Diseases*, 1998. 26(6):p. 1367.

PAPERS IN PREPARATION (RESEARCH COMPLETED)

SELECTED ABSTRACTS

1. Ghannoum MA and Edwards JE, Jr. 1991. Candida adherence to epithelial cells. *Les Adhesines Fongiques*, Institut Pasteur, Paris.
2. Filler SG, Ibe BO, Raj JU, Edwards JE, Jr. 1991. *Candida* activates endothelial cells to release prostaglandins. Presented at the national meeting of the American Federation for Clinical Research. Seattle, WA. *Clin. Res.* 39:147A.
3. Filler SG, Ibe BO, Raj JU, Edwards JE Jr. *Candida* activates endothelial cells to release prostaglandins. Presented at the national meeting of the American Federation for Clinical Research. Seattle, WA. May 1991. *Clin Res* 1991;39:147A.
4. Filler SG, Ibe BO, Raj JU, Edwards JE Jr. Endothelial cell recovery from cyclooxygenase inhibition is enhanced by *Candida albicans*. Presented at FASEB meeting. Anaheim, CA. April 1992. *FASEB J* 1992;6:5130A.
5. Filler SG, Ibe BO, Raj JU, Edwards JE, Jr. 1992. Endothelial cell recovery from Cyclooxygenase inhibition is enhanced by *Candida albicans*. Presented at FASEB meeting. Anaheim, CA. *FASEB J.* 6:5130A.

6. Filler SG, Ibe BO, Raj JU, Edwards JE, Jr. 1992. Endothelial cell release of prostaglandins in response to *Candida albicans*; stimulation of cyclooxygenase, phospholipase A₂, but not protein kinase C. Abstract 41. Presented at the annual meeting of the Infectious Diseases Society of America. Anaheim, CA.
 7. Ghannoum M, Ibrahim A, Fu Y, Shafiq M, Edwards JE, Jr, and Criddle R. 1992. Susceptibility testing of *Cryptococcus neoformans* employing a broth microdilution technique. The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, California.
 8. Ghannoum MA, Filler SG, Ibrahim A, Edwards JE, Jr. 1992. Modulation of the interaction of *Candida albicans* and endothelial cells by selected antifungal agents. The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, California.
 9. Alcouloumre MS, Ghannoum MA, Ibrahim A, Selsted ME, and Edwards JE, Jr. 1992. Susceptibility of *Cryptococcus neoformans* to defensin NP-1. The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, California.
 10. Filler SG, Swerdloff JN, Edwards JE, Jr. 1993. Endothelial cell phagocytosis of *Candida albicans* is required for endothelial cell injury. Abstract 55. Presented at the annual meeting of the Infectious Diseases Society of America. New Orleans, LA.
 11. Witt MD, Mortara LA, Larsen RA, Lewis RJ, Edwards JE, Jr., and Ghannoum MA. 1993. In vitro susceptibility of *Cryptococcus neoformans* predicts failure of primary therapy with fluconazole in patients with cryptococcal meningitis and AIDS. In the International Conference on AIDS, Berlin.
 12. Ghannoum MA, Radner AB, Ritchie JA, Ibrahim AS, and Edwards JE, Jr. 1993. Effects of AnBisome on *Candida albicans* interactions with endothelial cells. 93rd General Meeting of the American Society for Microbiology. Atlanta, Georgia.
 13. Ghannoum MA, Mortara LA, Fu Y, Ibrahim AS, Shafiq MC, Edwards JE, Jr and Criddle RS. 1993. Determining optimal antifungal combinations for *Candida albicans*. Presented at the 93rd General Meeting of the American Society for Microbiology. Abstract # F-9, Atlanta, Georgia.
 14. Ibrahim AS, Alcouloumre MS, Filler SG, Mortara LA, Edwards JE, Jr, Ghannoum MA. 1993. Adherence to and damage of endothelial cells by *Cryptococcus neoformans*: Comparison between acapsular and encapsulated strains. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract #55. New Orleans, Louisiana.
 15. Yeaman MR, Sullam PM, Dazin PF, Ghannoum MA, Edwards JE, Jr, Bayer AS. 1993. Platelet microbicidal protein augments fluconazole-induced reduction of *Candida* adherence to platelets *in vitro*. 33rd ICAAC Meeting, New Orleans, LA.
-

16. Ibrahim AS, Alcouloumre MS, Filler SG, Mortara LA, Edwards JE, Jr, Ghannoum MA. 1993. Adherence to and damage of endothelial cells by Cryptococcus neoformans. National Cooperative Drug Discovery Groups for the Treatment of Opportunistic Infections. Bethesda, MD.
17. Alcouloumre MS, Ghannoum MA, Ibrahim AS, Selsted ME, Edwards JE, Jr. 1993. In vitro activity of defensin NP-1 against Cryptococcus neoformans. National Cooperative Drug Discovery Groups for the Treatment of Opportunistic Infections. Bethesda, MD.
18. Witt MD, Lewis RJ, Larsen RA, Mortara LA, Edwards JE, Ghannoum MA. 1993. In vitro susceptibility of Cryptococcus neoformans predicts failure of primary therapy with fluconazole in patients with cryptococcal meningitis and AIDS. Abstract #Q154. In: Abstracts of the 22nd Keystone Symposium. Journal of Cellular Biochemistry s17E:24.
19. Radner AB, Ghannoum MA, Bayer AS, Edwards JE, Jr, Yeaman MR. 1994. In vitro activity of platelet microbicidal proteins against Candida albicans: quantitative comparison with fluconazole and amphotericin B. XII Congress of the International Society for Human and Animal Mycology, Adelaide, South Australia.
20. Ghannoum MA, Spellberg BJ, Ibrahim AS, Currie B, Spitzer E, Edwards JE, Jr, Casadevall A. 1994. Susceptibility and sterol pattern of Cryptococcus neoformans: effect of fluconazole. XII Congress of the International Society for Human and Animal Mycology. Adelaide, South Australia.
21. Ghannoum MA, Witt M, Espinel-Ingroff A, Ritchie J, Larsen R, Edwards JE, Jr. 1994. Correlation of in vitro testing of Cryptococcus neoformans with in vivo outcome: a comparison of two microdilution methods. 94th General Meeting of the American Society for Microbiology, Las Vegas, Nevada.
22. Witt MD, Lewis RJ, Larsen RA, Ritchie JA, Edwards JE, Jr, Ghannoum MA. 1994. Predicting treatment failure with fluconazole in acute AIDS-associated cryptococcal meningitis: a comparison of microdilution and macrodilution methods of susceptibility testing. 94th General Meeting of the American Society for Microbiology, Las Vegas, Nevada.
23. Radner AB, Ghannoum MA, Edwards JE, Jr, Bayer AS, Yeaman MR. 1994. Platelet microbicidal protein (PMP2) enhances the candidacidal activities of amphotericin B and fluconazole in vitro. 94th General Meeting of the American Society for Microbiology, Las Vegas, Nevada.
24. Filler SG, Hobbs C, Ibrahim AS, Edwards JE, Jr, Ghannoum MA. 1994. *Candida krusei* contains novel membrane sterols. Abstract C35. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL.

25. Ibrahim AS, Filler SG, Ritchie JA, Edwards JE, Jr, Ghannoum MA. 1994. Analysis of virulence factors of *Candida albicans* correlation between in vitro and in vivo data. Abstract B24. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL.
 26. Ghannoum MA, Fu Y, Fonzi W, Ibrahim AS, Filler SG, Edwards JE, Jr. 1994. Cloning and characterization of a candidal phospholipase (Plipase) gene. Abstract B22. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL.
 27. Filler SG, Hobbs C, Fu Y, Ghannoum MA, Edwards JE, Jr. 1994. *Candida albicans* stimulates proto-oncogene expression in endothelial cells. Abstract 72. Presented at the annual meeting of the Infectious Diseases Society of America. Orlando, FL.
 28. Ibrahim AS, Sanati H, Edwards JE, Jr & Ghannoum MA. 1995. Characterization of lipid classes of *Cryptococcus neoformans*. Presented at the 95th General Meeting of the American Society for Microbiology. Abstract# F51 Washington, DC.
 29. Currie B, Sanati H, Ibrahim AS, Edwards, JE, Jr, Casadevall A & Ghannoum MA. 1995. Sterol composition and susceptibility of environmental *Cryptococcus neoformans* isolates to amphotericin B are changed by murine passage. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; Abstract # B74 San Francisco, California.
 30. Yeaman MR, Ibrahim AS, Ritchie JA, Filler SG, Bayer AS, Edwards, JE, Jr, Ghannoum MA. 1995. Sublethal concentrations of platelet microbial protein reduce *Candida albicans* interactions with vascular endothelial cells *in vitro*. Presented at the Infectious Diseases Society of America meeting. San Francisco, California.
 31. Filler SG, Pfunder A, Fu Y, Ghannoum MA, Edwards JE, Jr. 1995. *Candida albicans* stimulates cytokine production and adhesion molecule expression in endothelial cells. Abstract G104. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA.
 32. Fratti RA, Ghannoum MA, Edwards JE, Jr, Filler SG. 1995. Endothelial cell injury caused by *Candida albicans* is dependent on iron. Abstract G15. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA.
 33. Yeaman MR, Soldan S, Ghannoum M, Edwards JE, Jr, Filler SG, Bayer AS. 1995. Resistance to platelet microbicidal protein (PMP) in vitro confers increased virulence to *Candida albicans* in experimental infective endocarditis in vivo. Abstract B42. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA.
-

34. Fratti RA, Ghannoum MA, Edwards JE, Jr, Filler SG. 1996. Interferon- protects endothelial cells from damage caused by *Candida albicans* by inhibiting endothelial cell phagocytosis. Abstract B58. Presented at the Fourth Conference on *Candida* and Candidiasis: Biology, Pathogenesis and Management. San Diego, CA.
35. Fratti RA, Edwards JE, Jr, Filler SG. 1996. Mechanisms of candidal adherence to and damage of endothelial cells. Abstract 203. Presented at the annual meeting of the Infectious Diseases Society of America. New Orleans, LA.
36. Ibrahim AS, Filler SG, Sanglard D, Edwards, JE, Jr, & Hube B. 1997. Interactions Between endothelial cells and secreted aspartyl proteinase-negative mutants of *Candida albicans*. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; Abstract # B9. Toronto, Ontario, Canada.
37. Tsuchimori N, Filler SG, Sharkey LL, Edwards JE Jr, Fonzi WA. September 1997. Role of ECE2 (Extent of Cell Elongation) in human endothelial cell injury caused by *Candida albicans*. Abstract B-38. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada.
38. Rieg G, Johnston D, Ibrahim AS, Filler S, Edwards JE, Jr. 1998. In vitro activity voriconazole in combination with amphotericin B or 5-flucytosine against clinical fluconazole resistant *Candida albicans*. Abstract J-11. Presented at the 38th Interscience conference on antimicrobial agents and chemotherapy. San Diego, California.
39. Filler SG, Joshi M, Phan QT, Diamond RD, Edwards JE Jr, Yeaman MR. Platelets protect vascular endothelial cells from injury due to *Candida albicans*. Abstract 2163. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 1999.
40. Fu Y, Ibrahim AS, Chen Y-C, Han Y, Filler SG, Cutler JE, Edwards JE Jr. Role of ALS1 in the virulence of *Candida albicans*. Abstract 286. Presented at the 37th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, PA, November
41. Cannon RRM, French SW, Mosher S, Edwards JE Jr, Filler SG. Local expression of cytokines and leukocyte adhesion molecules at sites of hematogenously disseminated candidiasis *in vivo*. Abstract 1112. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. September 2000.
42. Loza L Jr, Filler SG, Edwards JE Jr, Fu Y. Use of site-directed mutagenesis to identify the endothelial cell-binding region of the *Candida albicans* ALS1 gene product. Abstract 2126. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. September 2000.
43. Sheppard DC, Fu Y, Ibrahim AS, Filler SG, Edwards JE. "*Candida albicans* ALS1

Encodes an adhesin that regulates hyphal formation downstream of EFG1." Slide presentation, 40th Interscience Conference of Antimicrobial Agents and Chemotherapy. Toronto, 2000.

44. Sheppard DC, Fu Y, Ibrahim AS, Edwards JE, Filler SG. "The chromosomal location of EFG1 has a major impact on the morphology and virulence of *C. albicans*." Abstract F-49. Presented at the 101st General Meeting of the American Society for Microbiology, Orlando, Florida, May 2001.

APPEARS THIS WAY
ON ORIGINAL